摘要 |
A method of hormone replacement therapy involves the administration of oestrogen together with an amount of antiprogestin which inhibits oestrogen-induced endometrial proliferation without inducing a menstruation and without a progestin presence, whilst the oestrogen is in the amount effective for inhibition of oestrogen-induced endometrial proliferation and for producing of a state of substantial menopause. Oestrogen and antiprogestin are an effective component of the pharmaceutical preparation in the oral form or in the form with sustained action, whilst daily dosage contains 0.5 to 10 mg of antiprogestin, preferably 1 to 5 mg of antiprogestin. Antiprogestin according to the invention is a progestin receptor antagonist, particularly mifepristone, i. e. RU 486, whilst the amount of it keeps the oestrogen effect for bone protection.
|